4480.T Stock Today: March 31 — Medley to Buy Recruit Medical Career for ¥1.03B

Medley 4480.T stock is in focus after Medley agreed to acquire Recruit Medical Career for about ¥1.03 billion. Medley (4480.T) will take over the entire business via a new company, with closing targeted for August 3, 2026. The unit generated ¥2.65 billion in FY2025 revenue, expanding physician and pharmacist hiring plus RPO/BPO capabilities. Investors now weigh share gains and margin leverage from the added scale. We outline what this means for Medley 4480.T stock, valuation, catalysts, and trading setup in Japan.

Acquisition recap: scope, price, and fit

Medley will acquire all businesses of Recruit Medical Career for about ¥1.03 billion through a new company, with closing slated for August 3, 2026. The transaction transfers physician and pharmacist hiring support and related services to Medley. Management frames the deal as a scale and capability boost for healthcare staffing in Japan. Details align with local reports. See coverage from Nikkei.

Recruit Medical Career contributed ¥2.65 billion revenue in FY2025, bringing established relationships across hospitals, clinics, and pharmacies. These fit Medley’s JobMedley platform and its RPO/BPO offerings. The acquired pipelines should shorten time-to-fill and deepen client stickiness. For Medley 4480.T stock, the added volume can support operating leverage if integration costs stay contained and client retention holds through the transition.

Scale matters in Japan healthcare staffing, where specialized roles face tight supply and high compliance demands. The acquisition broadens candidate pools and service breadth, enabling cross-sell from job postings to RPO/BPO. For Medley 4480.T stock, the prize is share gains and margin uplift from higher average revenue per client and better utilization. Execution will decide whether benefits outpace integration and onboarding expenses.

How the market is pricing Medley now

Latest available data show shares at ¥1,878, up ¥36 (+1.95%) on the day, with a ¥1,863–¥1,904 range. The 52-week span is ¥1,725–¥3,720. Performance trends remain soft: YTD −18.76% and 1Y −41.78%, even as shares held firm post-announcement. For Medley 4480.T stock, stability after deal news suggests investors see strategic logic while awaiting proof on margins and growth.

Medley trades at about 1.60x sales, 1.80x EV/sales, P/B 4.36, and a high earnings multiple (P/E circa low-60s). ROE stands near 5.76%. On March 27, 2026, the Company Rating registered B- with a Neutral stance. For Medley 4480.T stock, multiples imply the market prices in execution, making delivery on synergies and profit expansion the key rerating driver.

TTM gross margin is roughly 63.0%, operating margin 5.84%, and net margin 2.65%. Leverage is moderate with debt-to-equity around 1.09 and a current ratio near 1.29. Intangibles comprise about 56% of assets, and will likely rise on acquisition accounting. For Medley 4480.T stock, watch goodwill levels, interest coverage, and cash generation as indicators of financial flexibility during integration.

Catalysts, risks, and trading setup

Earnings are scheduled for May 14, 2026, when we expect commentary on pro forma contribution, integration costs, and client migration plans. Ahead of the August 3 closing, milestones include regulatory and contractual consents, employee transfers, and systems cutover. For Medley 4480.T stock, updated guidance and any color on cross-sell pipelines and RPO/BPO wins could move expectations in Japan.

Key risks include client attrition, onboarding costs, and potential regulatory or data-handling issues in healthcare staffing. Useful checkpoints: retention rates, gross margin trend, and sales cycle length post-migration. Local media outline the scope and intent of the transaction, supporting these focus areas for investors MA Online. For Medley 4480.T stock, clean execution will be essential.

Technicals are neutral: RSI 47.38, ADX 22.74. Price sits near the Bollinger mid-band (¥1,860); bands at ¥1,747 and ¥1,975 flag key levels. The 50-day average at ¥2,181 remains overhead resistance. ATR of ~¥86 suggests typical daily swings. For Medley 4480.T stock, sustained closes above ¥1,975 open room toward ¥2,180, while support sits near ¥1,750.

Final Thoughts

For investors, the acquisition of Recruit Medical Career is a sensible scale-up that can enrich Medley’s physician and pharmacist pipelines and deepen its RPO/BPO offerings. The price tag (¥1.03 billion) looks manageable relative to the target’s ¥2.65 billion FY2025 revenue, but integration quality will drive outcomes. Focus on three items: client retention through closing, visibility on cross-sell wins, and the margin path as costs roll off. Technically, watch ¥1,975 resistance and the 50-day near ¥2,181 for confirmation. With fundamentals carrying mid-60s gross margin and moderate leverage, Medley 4480.T stock can re-rate if management delivers clean execution, stronger operating leverage, and clear guidance at the May 14 update. Until then, position sizing around ATR and defined stop levels can help manage risk.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.